In clinical work with women in midlife, the story often goes like this: she has been in treatment for depression or anxiety for several years. The treatment has helped, partially. She is managing. But something doesn't fully resolve, and neither she nor her previous clinicians have connected her symptoms to the stage she is in.
She is 44, or 47, or 51. She is in perimenopause. And it has not come up in her treatment.
In my experience, this is a common presentation. The mental health burden of the perimenopausal transition is one of the most robustly documented and least communicated findings in women's health research. Women arrive in therapy carrying symptoms that are predictable, biologically anchored, and often treatable - and they arrive having assumed for years that something was personally wrong with them.
The numbers that matter
Research suggests that women in perimenopause face roughly two to four times the risk of depressive symptoms compared with premenopausal women, with the size of the effect varying considerably between studies and between women. The signal is specific and concentrated in the transition period - the years of hormonal fluctuation before menopause is complete - rather than after.
The SWAN study, one of the most important longitudinal studies of women's health across the menopausal transition, followed over 3,000 women across five ethnic groups, with later analyses tracking a smaller subgroup for thirteen years. It found that depression risk rose during the menopausal transition, alongside the life circumstances women were carrying through the same years - the biology and the context both in play. Risk was higher during perimenopause and the early postmenopause than before it.
One finding from SWAN's thirteen-year follow-up stands out. In the sub-study that tracked 443 women through midlife, 59% of those with a prior history of depression had another episode over those years. Among the women with no such history, the figure was 28%. That is one site and one cohort, so it is a good finding rather than a settled law, and the gap is still wide enough to matter clinically. It is also almost never communicated to women in advance.
Why it is not just hormones
The hormonal dimension of perimenopausal mood disturbance is real and important. Estrogen modulates serotonin, dopamine, and GABA systems directly. Erratic fluctuations in estrogen during perimenopause - which can begin years before the final menstrual period - are thought to destabilise these neurotransmitter systems. The result can go beyond low mood to include anxiety that feels physical and unexplained, irritability that arrives disproportionately, cognitive fog, sleep disruption, and a pervasive sense that something is fundamentally wrong without a clear reason.
But hormones alone do not fully explain the pattern. Research suggests that a history of depression strongly predicts perimenopausal depression and current stress adds to the risk, and in SWAN, health and psychosocial factors were in some cases more important than menopausal status for high depressive symptoms.
My reading is that perimenopause is a period in which the biology amplifies what is already psychologically unresolved. Women who carry histories of trauma, chronic invalidation, or relational difficulty - and who have managed these through the strategies that midlife eventually makes unsustainable - seem, in my experience, to be at heightened risk during this window.
The biological changes do not create the psychological material. They remove some of the buffering capacity that kept it manageable.
What gets missed in treatment
Many women presenting with depression or anxiety in their forties are prescribed antidepressants without the hormonal context being considered. Sometimes this is appropriate - SSRIs and SNRIs have been shown to work for perimenopausal mood symptoms, and for moderate to severe depressive disorder they remain a primary treatment option. The issue is reflexive prescription that treats one layer without attending to the others.
FIGO's 2026 best-practice recommendations on mental health at menopause are now explicit on this point. They identify transdermal estradiol as preferred for managing mood swings, especially in women with metabolic risk. They call for routine mental health screening as part of standard midlife care.
What this means practically is that a woman with a prior history of depression who presents to her GP in her mid-forties with mood symptoms should not simply be offered the same antidepressant she took before. The hormonal biology should be part of the clinical conversation. The psychological and relational context should be part of the clinical conversation. Treatment that addresses only one of these layers often gives only partial relief - and leaves the woman believing the problem is more intractable than it actually is.
What adequate support includes
Adequate support for perimenopausal mental health is integrated. It considers the neurobiological component - whether hormonal stabilisation is appropriate and, if so, in what form. It considers the psychological component - what the perimenopausal transition is surfacing in terms of identity, relationships, and unprocessed experience. And it holds both without collapsing one into the other.
For many women, perimenopause is the first time the psychological material they have been managing through competence, over-functioning, and emotional containment becomes impossible to maintain at the same level. What was contained begins to surface, and that calls for different attention from "take this and come back in six weeks."
It also requires time. The perimenopausal transition is not a brief event. It often lasts several years, and for some women close to a decade. Treatment that expects rapid resolution of a multi-year neurobiological and psychological process will consistently disappoint. The frame matters: this is a transition, and it needs to be treated as one.
The silence around it
What I find most significant, after years of working with women in this window, is the silence they experienced before arriving in therapy. They had spent years interpreting their symptoms as personal inadequacy. They assumed the depression returning meant they hadn't worked hard enough in previous therapy, or that they were fundamentally more fragile than they had believed. They had not been told that this was a predictable window, that their history made them statistically more vulnerable, that there was both a biological and a psychological component to address.
That silence has a cost. It compounds the symptoms with shame. And shame, in my clinical experience, is one of the most reliable ways to keep someone from seeking appropriate help.
The research exists. The clinical guidelines have shifted. What is still lagging is the transmission of that information to the women who need it - before the window opens, not after they have spent years inside it without a map.
References
- Bromberger, J. T., Matthews, K. A., Schott, L. L., Brockwell, S., Avis, N. E., Kravitz, H. M., Everson-Rose, S. A., Gold, E. B., Sowers, M., & Randolph, J. F., Jr. (2007). Depressive symptoms during the menopausal transition: The Study of Women's Health Across the Nation (SWAN). Journal of Affective Disorders, 103(1-3), 267-272. https://doi.org/10.1016/j.jad.2007.01.034
- Bromberger, J. T., Schott, L., Kravitz, H. M., & Joffe, H. (2015). Risk factors for major depression during midlife among a community sample of women with and without prior major depression: Are they the same or different? Psychological Medicine, 45(8), 1653-1664. https://doi.org/10.1017/S0033291714002773
- Khadilkar, S., Divakar, H., Benedetto, C., Genazzani, A., Ramos, D., Argale, E., Deshpande, G., Hickey, M., Filho, A. L. D. S., Herrera, E., & Balkrishnan, M. (2026). FIGO best practice recommendations for the mental health of women at menopausal age. International Journal of Gynecology & Obstetrics, 173(2), 588-601. https://doi.org/10.1002/ijgo.70943
If you want to name what is happening for you right now, take the free Midlife Quiz.
If this speaks to you, subscribe to my mailing list.
Subscribe